{
    "clinical_study": {
        "@rank": "63695", 
        "acronym": "BOOST\u00ae", 
        "arm_group": [
            {
                "arm_group_label": "IDegAsp BID + IAsp OD", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDeg OD + IAsp TID", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted globally. The aim of the trial is to compare efficacy of insulin\n      degludec/insulin aspart (IDegAsp) twice daily (BID) + insulin aspart (IAsp) once daily (OD)\n      versus basal bolus with insulin degludec (IDeg) OD + IAsp three times a day (TID) in\n      controlling glycaemia by evaluating glycosylated haemoglobin (HbA1c). The trial is an\n      extension to trial NN5401-3941 (NCT01680341)."
        }, 
        "brief_title": "A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HbA1c equal to or above 7.0% measured after 26 weeks of treatment in NN5401-3941\n             (NCT01680341), by central laboratory\n\n        Exclusion Criteria:\n\n          -  Uncontrolled or untreated severe hypertension defined as systolic blood pressure\n             equal to or above 180 mmHg and/or diastolic blood pressure equal to or above 100 mmHg\n\n          -  Impaired liver function, defined as alanine aminotransferase (ALAT) or aspartate\n             aminotransferase (ASAT) equal to or above 2.5 times upper limit of normal\n\n          -  Impaired renal function defined as serum-creatinine equal to or above 125 micromol/L\n             (equal to or above 1.4 mg/dL) for males and equal to or above 110 micromol/L (equal\n             to or above 1.3 mg/dL) for females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814137", 
            "org_study_id": "NN5401-4003", 
            "secondary_id": [
                "2012-003152-37", 
                "U1111-1132-2674"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "IDegAsp BID + IAsp OD", 
                "description": "For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs-  dose and dosing frequency of OAD should remain unchanged).", 
                "intervention_name": "IDegAsp", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDeg OD + IAsp TID", 
                "description": "For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs-  dose and dosing frequency of OAD should remain unchanged).", 
                "intervention_name": "IDeg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp BID + IAsp OD", 
                "description": "For subcutaneous (s.c., under the skin) administration once daily.\nDose of IDegAsp and IAsp are individually adjusted.", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDeg OD + IAsp TID", 
                "description": "For subcutaneous (s.c., under the skin) administration three times a day.\nDose of IDeg and IAsp are individually adjusted.", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 11, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenbrae", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94904"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92111"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spring Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91978"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34208"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kissimmee", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34741"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plantation", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33324"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Crystal Lake", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60012"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46254"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Slidell", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70461-4231"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waltham", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02453"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buckley", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49620"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lawrenceville", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08648"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toms River", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08755-8050"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kenosha", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53142-7884"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Ingbert", 
                        "country": "Germany", 
                        "zip": "66386"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kota Bharu, Kelantan", 
                        "country": "Malaysia", 
                        "zip": "16150"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denizli", 
                        "country": "Turkey", 
                        "zip": "20070"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Malaysia", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST\u00ae: INTENSIFY BID)", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Algeria: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Malaysia: Ministry of Health", 
                "Turkey: Ministry of Health Drug and Pharmaceutical Department", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c (glycosylated haemoglobin)", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 26"
        }, 
        "removed_countries": {
            "country": "Algeria"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814137"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of treatment emergent adverse events (TEAEs)", 
                "safety_issue": "No", 
                "time_frame": "During 26 weeks of treatment"
            }, 
            {
                "measure": "Number of treatment emergent hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "During 26 weeks of treatment"
            }, 
            {
                "measure": "Number of treatment emergent nocturnal (00:01-05:59) confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "During 26 weeks of treatment"
            }, 
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}